Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Milameline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.97 |
| ▸ | CHRM5 known ✓ | P08912 | 2/20 | 0.97 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.97 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.40 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Milameline SCHEMBL8730187 | 1.00 | CHRM2 (0.97) | CHRM2CHRM5CHRM1LMNACHRM4 | |
| Milameline SCHEMBL8730172 | 0.98 | CHRM2 (1.00) | CHRM2CHRM5CHRM1LMNACHRM4 | |
| Milameline SCHEMBL195143 | 0.98 | CHRM2 (1.00) | CHRM2CHRM5CHRM1LMNACHRM4 | |
| Hydrochloric Acid SCHEMBL9266191 | 0.82 | CHRM1 (0.67) | CHRM2CHRM5CHRM1LMNACHRM4 | |
| Hydrochloric Acid SCHEMBL9266187 | 0.82 | CHRM1 (0.67) | CHRM2CHRM5CHRM1LMNACHRM4 | |
| SCHEMBL12043330 | 0.80 | CHRM1 (0.69) | CHRM2CHRM5CHRM1LMNACHRM4 | |
| SCHEMBL10390529 | 0.79 | CHRM2 (0.68) | CHRM2CHRM5CHRM1LMNACHRM4 | |
| Hydrochloric Acid SCHEMBL9261273 | 0.79 | CHRM2 (0.62) | CHRM2CHRM5CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL9261270 | 0.79 | CHRM2 (0.62) | CHRM2CHRM5CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL9263269 | 0.79 | CHRM2 (0.62) | CHRM2CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119866336-A | Crystalline forms and salts of muscarinic receptor agonists | 尼克塞拉制药英国有限公司 | 2025-04-22 | — | — | CN | disclosed |
| CN-119039284-A | Oxadiazoles as agonists of muscarinic M1 and/or M4 receptors | 奈克斯拉制药英国有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-112585143-B | Bridging compounds as agonists of muscarinic M1 and/or M4 receptors | 奈克斯拉制药英国有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-112585135-B | Oxadiazoles as agonists of muscarinic M1 and/or M4 receptors | 奈克斯拉制药英国有限公司 | 2024-08-02 | — | — | CN | disclosed |
| WO-2024036005-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | NKMAX CO., LTD. (KR) | 2024-02-15 | — | — | WO | disclosed |
| CN-116848109-A | Pharmaceutical compounds | 赫普泰雅治疗有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-110944992-B | Pharmaceutical compounds | 赫普泰雅治疗有限公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-4019018-A1 | MUSCARINIC COMBINATION AND ITS USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | Chase Pharmaceuticals Corporation (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20190314354-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHASE PHARMACEUTICALS CORPORATION (US) | 2019-10-17 | — | — | US | disclosed |
| US-10307409-B2 | Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system | CHASE PHARMACEUTICALS CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| EP-3265466-A1 | PERIPHERAL-ANTICHOLINERGIC MUSCARINIC AGONIST COMBINATION | Chase Pharmaceuticals Corporation (US) | 2018-01-10 | — | — | EP | disclosed |
| WO-2017044714-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHASE PHARMACEUTICALS CORPORATION (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017044693-A1 | MUSCARINIC COMBINATION AND ITS USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHASE PHARMACEUTICALS CORPORATION (US) | 2017-03-16 | — | — | WO | disclosed |
| US-20160375001-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHASE PHARMACEUTICALS CORPORATION (US) | 2016-12-29 | — | — | US | disclosed |
| WO-2016144727-A1 | PERIPHERAL-ANTICHOLINERGIC MUSCARINIC AGONIST COMBINATION | CHASE PHARMACEUTICALS CORPORATION (US) | 2016-09-15 | — | — | WO | disclosed |
| EP-0808907-B1 | Compositions and methods for the detection of mycobacterium kansasii | GEN PROBE INC (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-1998030243-A1 | ACETYLCHOLINESTERASE INHIBITORS IN COMBINATION WITH MUSCARINIC AGONISTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | WARNER-LAMBERT COMPANY (US) | 1998-07-16 | — | — | WO | disclosed |
| EP-0808907-A2 | Compositions and methods for the detection of mycobacterium kansasii | GEN-PROBE INCORPORATED (US) | 1997-11-26 | — | — | EP | disclosed |
| US-5391754-A | Oximination a tetrahydropyridin-3-aldehyde, alkylation with a halides, salt formation | ROUSSEL UCLAF (FR) | 1995-02-21 | — | — | US | disclosed |
| WO-1993011767-A1 | TRANSDERMAL DELIVERY OF (E)-1,2,5,6-TETRAHYDRO-1-METHYL-3-PYRIDINE-CARBOXALDEHYDE-O-METHYLOXINE HCL AND RELATED COMPOUNDS IN THE TREATMENT OF COGNITIVE DISORDERS AND FOR ANALGESIA | WARNER-LAMBERT COMPANY (US) | 1993-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314354-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHRM3, CHRM2, CHRM4 | CHRM2 2/4885CHRM5 4/4885CHRM1 5/4885 |
| US-10307409-B2 | Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system | CHRM3, CHRM2, CHRM4 | CHRM2 2/4885CHRM5 4/4885CHRM1 5/4885 |
| US-20160375001-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHRM3, CHRM2, CHRM4 | CHRM2 2/4885CHRM5 4/4885CHRM1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.